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Abstract
Infection with the Gram-negative pathogen Prevotella intermedia gives rise to periodontitis and a growing number of
studies implies an association of P. intermedia with rheumatoid arthritis. The serine protease Factor I (FI) is the central
inhibitor of complement degrading complement components C3b and C4b in the presence of cofactors such as C4b-
binding protein (C4BP) and Factor H (FH). Yet, the significance of complement inhibitor acquisition in P. intermedia infection
and FI binding by Gram-negative pathogens has not been addressed. Here we show that P. intermedia isolates bound
purified FI as well as FI directly from heat-inactivated human serum. FI bound to bacteria retained its serine protease activity
as shown in degradation experiments with 125I-labeled C4b. Since FI requires cofactors for its activity we also investigated
the binding of purified cofactors C4BP and FH and found acquisition of both proteins, which retained their activity in FI
mediated degradation of C3b and C4b. We propose that FI binding by P. intermedia represents a new mechanism
contributing to complement evasion by a Gram-negative bacterial pathogen associated with chronic diseases.
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Introduction
Prevotella intermedia is regarded as an important causative agent of
periodontitis besides Aggregatibacter actinomycetemcomitans, Porphyromo-
nas gingivalis, Tannerella forsythia and Fusobacterium nucleatum [1].
Gingivitis and periodontitis are inflammatory diseases affecting the
surrounding and supporting tissues of the teeth and caused by
infection with microbial periodontal pathogens. Gingivitis is highly
prevalent affecting up to 90% of the world’s population and
represents an inflammation limited to soft gingival tissues while
periodontitis describes a severe manifestation of periodontal
disease characterized by the formation of tissue pockets associated
with irreversible damage of tissue and supporting bone, eventually
leading to tooth loss [2]. Recent findings support the correlation
between periodontitis and cardiovascular disease [3] and peri-
odontal pathogens have been detected in the coronary arteries
from patients afflicted with chronic periodontitis [4]. Moreover,
clinical studies as well as the presence of DNA of periodontal
pathogens in synovial fluid and serum, most frequently from P.
intermedia and P. gingivalis, suggest a link between periodontitis and
rheumatoid arthritis [5,6].
The complement system is composed of a set of proteolytic
enzymes and represents an essential part of innate immunity. It
exhibits its bactericidal properties upon cascade-like activation
reactions, which take place either through the classical pathway,
the lectin pathway or the alternative pathway. Antibodies attached
to pathogens or C1q bound to bacterial surfaces mediate
complement activation through the classical pathway, whereas
the lectin pathway is triggered by carbohydrate ligands. The
alternative pathway represents an activation loop of the afore-
mentioned pathways but can also be driven by the spontaneous
tick-over of C3 to hydrolyzed C3(H2O) or properdin binding.
Complement as a broad first line defense mechanism confronts
pathogens with an effective bactericidal environment. Activation
of complement leads either to opsonization of the pathogen for
phagocytosis, lysis through the formation of the membrane attack
complex, or the release of proinflammatory anaphylatoxins [7].
The omnipresent broad cytotoxicity of complement underlines the
importance of controlling its activation by inhibitors in order to
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prevent self-damage to host tissues. Inhibitors such as C4b-binding
protein (C4BP) and factor H (FH) inhibit the classical/lectin or the
alternative pathway, respectively, by serving as cofactors in
degradation of C4b and C3b by factor I (FI) as well as hindering
the formation and accelerating the decay of the C3 convertases
[8,9]. The serine protease FI has a serum concentration of 35 mg/
L and inhibits all complement pathways [10]. Its activity requires
the presence of cofactors such as C4BP and FH. C4BP is found in
human plasma at concentrations of ,200 mg/L [11] while the
concentration of FH in human plasma varies from 116 to 711 mg/
L [11,12]. Furthermore, serum proteins including complement are
present in the gingival fluid from inflamed periodontal tissue [13]
thus constituting partially also the proteins present in saliva [14].
Acquisition of complement inhibitors by various bacterial
pathogens, mainly the soluble inhibitors C4BP and FH, leading
to protection from activated complement, has been reported
previously [15,16]. Only a few periodontal pathogens have been
reported to bind these cofactors; binding of FH occurs to
preparations of the outer membrane protein 100 of Aggregatibacter
actinomycetemcomitans [17], P. gingivalis binds C4BP [18] and
Treponema denticola binds FH, which is subsequently cleaved by
the protease dentilisin [19]. So far only Staphylococcus aureus has
been shown to bind FI via clumping factor A (ClfA), which
appears to act as a cofactor to FI in degradation of C3b [20,21].
This leads to decreased phagocytosis efficiency by human
polymorphonuclear cells [22].
Here we show for the first time binding of FI to a Gram-
negative bacterial pathogen, P. intermedia. We also found that P.
intermedia captures C4BP and FH. All three inhibitors retain their
activity when bound to P. intermedia ATCC 25611. Thus, this study
provides insight into a new evasion strategy of a main periodontal
pathogen able to establish chronic infection.
Materials and Methods
Ethics statement
Normal human serum (NHS) was prepared from blood of
healthy volunteers after written informed consent had been
obtained with the specific permit by the ethics committee of Lund
University (permit number 418/2008).
Strains and culture conditions
P. intermedia OMZ 248 and OMZ 324, kindly provided by Ellen
V. G. Frandsen, Department of Oral Biology, Royal Dental
College, Aarhus, Denmark [23], MH6, isolated in Jena from a
patient suffering from severe chronic periodontitis, as well as the
type strain ATCC 25611 (American Type Culture Collection,
Manassas, VA) were cultured on Fastidious Anaerobe agar plates
for 4 days at 35uC in an anaerobic chamber (80% N2, 10% CO2,
10% H2) or in anaerobic jars containing an atmosphere depleted
of oxygen using Anaerogen sachets (Oxoid, Basingstoke, UK).
Several strains were employed as controls, with their culture
conditions described below. Streptococcus pyogenes CCUG 25571,
Moraxella catarrhalis RH4, M. catarrhalis DuspA1DuspA2 [24] were
cultivated on blood agar plates (supplemented with zeocin and
chloramphenicol for the mutant strain) at 37uC in an atmosphere
enriched with 5% CO2. S. aureus ATCC 25923 as well as S. aureus
Newman (wild type laboratory strain (T.J. Foster) were cultured on
tryptic soy broth agar plates, and Escherichia coli DH5a was
cultured on LB agar plates, all at 37uC in normal atmosphere.
Porphyromonas gingivalis W50 [25] and W83 [26] were cultivated for
7–8 days at 35uC on FAA agar plates in an anaerobic chamber.
During the initial screening of bacterial strains for their ability to
recruit FI on their surface, E. coli DH5a exhibited only weak FI
binding capacity, hence being chosen as an internal low binding
control for each binding experiment. S. aureus ATCC 25923 is a
strain associated with ClfA expression [27–29] and S. aureus
Newman has been shown to bind FI [20], thus FI acquisition by
these strains was anticipated. Porphyromonas gingivalis W50 and W83
[18] as well as M. catarrhalis RH4 bind C4BP [24], while S. pyogenes
strains have been shown to capture FH on their surface [30].
Conversely, S. aureus ATCC 25923 has been reported not to bind
FH [31]. Therefore, S. aureus ATCC 25923 and Newman (FI
binding positive controls) as well as E. coli DH5a (FI binding
negative control) served as control strains in FI binding
experiments, M. catarrhalis RH4, P. gingivalis W50 and W80
(C4BP binding positive controls) and M. catarrhalis RH4 DuspA1/2
as well as E. coli DH5a (C4BP binding negative controls) were
chosen to assess the binding capacity of P. intermedia strains in
C4BP binding experiments. Likewise, S. pyogenes CCUG 25571
(FH binding positive control) and S. aureus ATCC 25923 and E. coli
DH5a (FH binding negative controls) appeared to be appropriate
internal controls investigating FH acquisition by P. intermedia.
Proteins and antibodies
FI, C4BP and FH were purified from human serum as
described previously [11,32,33]. When higher concentrations of
FI were required for competition experiments recombinant FI
expressed in eukaryotic cells was used [34]. C3met and C4met
were derived from C3 and C4 respectively (Complement
Technology, Tyler, Tx). Briefly, C3 and C4 were incubated with
0.1 M methylamine hydrochloride pH 8.0 for 1 h at 37uC and
subsequently dialyzed against 50 mM Tris-HCl, 150 mM NaCl,
pH 8.0. The polyclonal rabbit antibody PK9205 against human
FI was raised in-house. Goat anti human FI antiserum A313 was
purchased from Quidel (San Diego, CA) and rabbit anti goat
horseradish peroxidase (HRP)-conjugated antibody was obtained
from Dako (Glostrup, Denmark).
Direct binding of 125I-labeled FI, C4BP and FH by P.
intermedia
Serum purified proteins were labeled with 125I using Iodobeads
(Pierce, Rockford, IL) or the chloramine T method [35] (specific
activities between 0.22–0.35 MBq/mg protein). Binding experi-
ments were essentially performed as described earlier [36]. Briefly,
all P. intermedia as well as the control strains were harvested from
plates and resuspended in phosphate buffered saline (PBS)
(137 mM NaCl, 2.7 mM KCl, 1.47 mM KH2PO4, 8 mM
Na2HPO4) supplemented with 1% bovine serum albumin (BSA),
pH 7.0, to obtain an OD600 of 0.5. Bacteria were harvested and
resuspended in 1/100 volume PBS with 1% BSA before
proceeding with the binding assay. Twenty ml of the bacterial
suspension (approximately 26109 bacteria) were mixed with
250 kcpm 125I-FI, or 500 kcpm 125I-C4BP and 125I-FH, respec-
tively, and incubated for 1 h at RT in a total reaction volume of
40 ml. Protein bound to bacteria was separated from unbound
protein by centrifugation through 250 ml of 20% sucrose for 3 min
at 10,000 rpm (Biofuge 13, Heraeus Sepatech, Osterode, Ger-
many). The radioactivity associated with pellets and supernatants
was measured in a gamma counter (Gamma Master 1277, LKB
Wallac, Turku, Finland). Samples containing 125I-labeled proteins
that were mixed with buffer alone without bacteria served as
negative controls.
In order to elucidate the specificity and to further characterize
protein binding by P. intermedia, competition experiments with the
type strain P. intermedia ATCC 25611 were performed. First, 20 ml
bacterial suspension were mixed with unlabelled FI (final
concentrations 0–5000 nM/0–0.44 mg/ml) as well as 250 kcpm
Binding of Complement Inhibitors by P. intermedia
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125I-FI in a total reaction volume of 40 ml and samples were
incubated for 1 h at RT. Unbound protein was separated from the
bacteria containing fraction by centrifugation through 20%
sucrose and radioactivity measured as described above. In
competition experiments with FH and C4BP likewise to the
competition experiments with FI, 20 ml of the bacterial suspen-
sions were mixed with labeled and unlabelled proteins in a total
reaction volume of 40 ml. Binding of 500 kcpm 125I-FH was
investigated in the presence of 7.5 mg (final concentration
1.25 mM) unlabeled FH, whereas binding of 250 kcpm 125I-
C4BP was determined in the presence of 30 mg (final concentra-
tion 1.32 mM) unlabeled C4BP and bacterial suspensions that had
been adjusted to an OD600 of 0.5 before. Otherwise, samples were
treated as described for FI competition experiments. The
sensitivity of the interaction to ionic strength was tested adding
increasing concentrations of NaCl to the reaction starting from
physiological NaCl concentration (150–950 mM). Prevotella inter-
media is an obligate anaerobic pathogen. Therefore, binding
experiments with P. intermedia 25611 were also conducted under
anaerobic conditions in order to rule out whether the presence of
oxygen during the binding reaction leads to increased FI
acquisition. At least three independent experiments were per-
formed in duplicates; averages and standard deviations (SD) were
calculated for evaluation of the data.
Binding of FI from serum by P. intermedia strains
Maxisorp microtitre plates (Nunc, Roskilde, Denmark) were
coated over night at 4uC with 10 mg/ml (67 nM) of the polyclonal
rabbit anti human FI antibody PK9205 in coating buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.6). P. intermedia strains as well as
S. aureus ATCC 25923 and Newman (FI binding positive control)
and E. coli DH5a (FI binding negative control) were taken from
agar plates and resuspended in gelatin-veronal buffer (GVB)
(144 mM NaCl, 1.8 mM Na-barbital, 3.1 mM barbituric acid,
0.1% gelatin, pH 7.35) to obtain an OD600 of 0.5 and harvested
by centrifugation thereafter. The pellet was resuspended in 1/10
volume GVB and bacteria prepared in duplicates for the FI
consumption assay. Human serum, which had been incubated at
56uC for 30 min (heat inactivated normal human serum, HI-
NHS), 50 ml diluted to 2% in GVB was mixed with 50 ml of the
bacterial suspension and samples were incubated for 1 h at RT
and subsequently spun down. Thereafter, 50 ml of the superna-
tants were added to the wells of the microtiter plate, which was
washed with immunowash (50 mM Tris-HCl, 150 mM NaCl,
0.1% (v/v) Tween 20, pH 7.5), blocked with quench solution
(immunowash with 0.3% fish gelatin, Nordic, Ta¨by, Sweden) for
1 h at 37uC and washed again before adding the supernatants.
Then, plates were incubated for 1 h at RT. Thereafter, plates were
washed three times with immunowash followed by addition of the
primary antibody (goat anti-human FI A313 diluted 1:2,500 in
quench solution). The plates were incubated for 1 h at RT and
washed thrice as indicated above. Then, the secondary antibody
(HRP-conjugated rabbit anti-goat, dilution 1:2,500) was added to
the wells and the plates were incubated again for 1 h at RT. After
three washing steps plates were developed using 1,2-phenylenedi-
amine dihydrochloride (OPD tablets, Dako, Glostrup, Danmark)
and read at 490 nm in a Cary50 Bio UV spectrometer, 50MPR
microplate reader (Varian, Palo Alto, CA). Values measured for
wells containing only the bacteria without HI-NHS where the
primary antibody had been omitted were used for background
normalization. The relative amount of FI bound to P. intermedia
was calculated as follows: The value from wells with 1% HI-NHS
in GVB without bacteria was set to 100%. The amount by which
total FI in the supernatants was reduced was considered to be
bound by bacteria and the relative amount depleted by bacteria
was expressed as percent FI bound from 1% HI-NHS. Averages of
duplicates were used for calculations; data sets of three
independent experiments were analyzed by calculating averages
and SD.
Activity of proteins bound to P. intermedia ATCC 25611
P. intermedia ATCC 25611 was picked from plates, resuspended
in PBS, 1% BSA pH 7.0 to obtain an OD600 of 0.5 and harvested
by centrifugation. Resulting pellets were finally resuspended in 1/
100 volume of PBS, 1% BSA, pH 7.0. P. intermedia is known to
produce proteases such as Interpain A, able to degrade C3 and C4
alpha chains [37]. Therefore, in order to minimize background
degradation by P. intermedia ATCC 25611 aliquots (20 ml,
approximately 26109 bacteria) of the bacterial suspensions were
incubated for 30 min at 56uC besides adding 2 mM E-64 (Sigma-
Aldrich, St. Louis, MO) together with the substrates C3 or C4
later when preparing samples for the degradation reaction. The
protein binding assays were performed in a total reaction volume
of 40 ml. Bacteria were either mixed with 5 mg, 10 mg and 15 mg FI
(final concentration 125 ng/ml (1.42 mM), 250 ng/ml (2.84 mM)
and 375 ng/ml (4.26 mM)) or C4BP (final concentration 125 ng/ml
(0.22 mM), 250 ng/ml (0.44 mM) and 375 ng/ml (0.66 mM)), or
1 mg, 2 mg and 5 mg FH (final concentration 0.025 mg/ml
(0.16 mM), 0.05 mg/ml (0.32 mM), 0.125 mg/ml (0.8 mM)) and
further incubated for 1 h at RT. Finally, bacteria were washed
once with 50 mM Tris, 150 mM NaCl, pH 7.4 and transferred to
fresh reaction tubes.
To determine whether FI bound to P. intermedia ATCC 25611
retained its protease activity, degradation assays with 125I-C4b
were performed. Bacteria were mixed with 2 mM E-64 to prevent
unspecific degradation by cysteine proteases. Thereafter, C4met
(50 mg/ml; 0.26 mM), C4BP (100 mg/ml; 0.18 mM), trace amounts
of 125I-C4b and 50 mM Tris, 150 mM NaCl, pH 7.4 were added
in a final reaction volume of 50 ml. Samples were incubated for 4 h
at 37uC, centrifuged and resulting supernatants were run on a 10–
15% SDS-PAGE gradient gel. Gels were dried and protein bands
visualized by autoradiography using a radioisotope imager
(Fujifilm, Tokyo, Japan). Bacteria, which were preincubated with
buffer without FI served as a negative control and reference for
quantification of the results. Further controls were samples in
which bacteria were omitted and either FI (5.28 mg/ml; 60 nM)
and C4BP (100 mg/ml; 0.18 mM) (positive control) or only FI
(5.28 mg/ml; 60 nM) without cofactor (negative control) were
added. Data were quantified with the Image Gauge Software
(Fujifilm, Tokyo, Japan).
To assess cofactor activity of bound C4BP in degradation
assays, the effect of surface-bound C4BP on C4b degradation was
investigated. In these experiments, FI (5.28 mg/ml; 60 nM) was
added instead of C4BP after the binding reactions with C4BP were
completed. The negative control without bacteria as described
above contained C4BP (100 mg/ml; 0.18 mM) instead of FI.
Finally, all samples were incubated for 1.5 h at 37uC.
Functional integrity of FH bound to P. intermedia ATCC 25611
was assessed in degradation assays with 125I-C3b. Briefly, bacterial
suspensions were prepared as indicated above, mixed with 2 mM
E-64, C3met (150 mg/ml; 0.81 mM), FI (5.28 mg/ml; 60 nM), and
trace amounts of 125I-C3b. The final volume was adjusted to 50 ml
by adding 50 mM Tris, 150 mM NaCl, pH 7.4. Samples were
incubated for 1.5 h at 37uC and thereafter treated as described
above. In addition to the negative control, in which FH was
omitted, an additional negative control without bacteria was
included, in which FI was omitted. Moreover, a positive control
Binding of Complement Inhibitors by P. intermedia
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without bacteria containing FH (20 mg/ml; 32 mM) and FI
(5.28 mg/ml; 60 nM) was prepared.
Results obtained from the degradation assays were evaluated
using one-way ANOVA followed by Tukey’s post-hoc test on
samples containing bacteria and compared to bacteria-containing
samples, which had been incubated with buffer instead of FI,
C4BP, or FH.
In order to rule out false positive binding by bacteria treated
with elevated temperature and to show that binding of the
respective proteins occurs under these conditions, P. intermedia
ATCC 25611 was incubated at 56uC for 30 min and binding
assays were performed as described with the 125I-labeled proteins;
binding of FI, C4BP and FH was compared to binding of these
proteins by untreated bacteria.
The contrast and brightness levels of images showing gels of
degradation assays were minimally adjusted in whole images using
Photoshop software (Adobe Systems, San Jose, CA) on a
Macintosh computer (Apple, Cupertino, CA). Relevant lanes were
selected and pictures were trimmed using the same software.
Statistical analysis
One-way ANOVA followed by Tukey’s Multiple Comparison
Test was used for statistical evaluation of the data applying
GraphPad Prism software (La Jolla, CA).
Results
P. intermedia strains bind purified FI and FI in complete
serum
We chose the type strain P. intermedia ATCC 25611 as well as
three clinical isolates to investigate FI acquisition by these Gram-
negative pathogens. Besides the Gram-positive S. aureus strains
ATCC 25923 and Newman (internal positive controls) we
included also a Gram-negative bacterium E. coli DH5a, as a
negative control. P. intermedia ATCC 25611, OMZ 248, OMZ
324, MH6 bound purified FI whereas no significant binding was
observed for E. coli DH5a as well as S. aureus ATCC 25923 and
Newman using this experimental setup (Fig. 1A). The binding
capacity of both S. aureus strains was remarkably low, however
consistent with the reported binding properties of this species.
Binding of FI by S. aureus has been found to be sensitive to the
presence BSA [38], which was a buffer supplement in our binding
experiments. In order to evaluate the role of BSA on FI binding we
performed an experiment where we omitted BSA and found that
BSA had only a minimal effect on FI binding (data not shown). FI
binding appeared to be a slightly elevated in the absence of BSA,
however the effect was not statistically significant. Other factors
than BSA, such as culture conditions, might affect FI binding by S.
aureus [39] and result in our inability to detect significant levels of
FI binding by previously reported binders S. aureus ATCC 25923
and Newman.
Next we sought to prove that P. intermedia strains selectively bind
FI from serum. To this end, we used HI-NHS to avoid risk of
detecting FI bound to C4b/C3b deposited on the bacterial
surface. Thus, we investigated the consumption of FI from 1% HI-
NHS in the presence of the various P. intermedia strains as well as E.
coli DH5a (FI binding negative control) and S. aureus ATCC 25923
and Newman (FI binding positive controls). This experimental set
up was chosen in order to avoid potential artifacts caused by direct
binding of antibodies to P. intermedia [40,41]. All our P. intermedia
strains acquired significant amounts of FI from HI-NHS as
compared to FI consumption by E. coli DH5a (Fig. 1B). S. aureus
Newman bound FI from serum significantly in contrast to the
results obtained from binding experiments with purified 125I-FI. S.
aureus ATCC 25923 did not consume significant amounts of FI
from HI-NHS as compared to E. coli DH5a. These data confirm
that P. intermedia strains also acquire FI under more physiological
conditions in the presence of all serum proteins.
The specificity of FI binding by P. intermedia was confirmed by
reducing significantly binding of 125I-FI by strain ATCC 25611
Figure 1. P. intermedia strains bind purified 125I-FI and FI from HI-NHS. A) P. intermedia ATCC 25611, OMZ 248, OMZ 324, MH6, S. aureus
strains ATCC 25923 and Newman (FI binding positive control) as well as E. coli DH5a (FI binding negative control) were incubated with 125I-FI
(250 kcpm). Bound and free FI were separated by centrifugation through sucrose, the radioactivity associated with pellets and supernatants was
measured in a gamma counter and the percentage of radioactivity bound to the pellet was calculated. Samples containing 125I-labeled FI that was
incubated with buffer alone served as a negative control. Averages of three independent experiments performed in duplicates are shown; error bars
show SD. One-way ANOVA followed by Tukey’s post-hoc test was used for statistical evaluation of the data as compared to the negative control
(*** p,0.001; ** p,0.01, n.s., not significant). B) HI-NHS (1%) was mixed with P. intermedia ATCC 25611, OMZ 248, OMZ 324, MH6 or S. aureus strains
ATCC 25923 and Newman, as well as E. coli DH5a and samples were incubated for 1 h at RT followed by centrifugation. Aliquots of the supernatants
were added to the wells of a microtiter plate coated with the polyclonal anti-FI antibody PK9205. Captured FI was detected with a polyclonal goat anti-FI
antibody. Binding of FI to bacteria resulted in a decreased FI concentration in the serum. This value was then used to calculate bound FI. The graph
shows averages of three independent experiments performed in duplicates and error bars indicate SD. One-way ANOVA followed by Tukey’s post-hoc
test was applied for statistical evaluation of the data as compared to values calculated for E. coli DH5a (** p,0.01; * p,0.05, n.s., not significant).
doi:10.1371/journal.pone.0034852.g001
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Figure 2. Competition of 125I-FI binding by P. intermedia with unlabelled FI and sensitivity of FI binding to ionic strength. A) Bacteria
were mixed with unlabelled FI (final concentrations 0–5000 nM/0–0.44 mg/ml) and incubated with 250 kcpm 125I-FI for 1 h at RT and bound protein
was measured as described in Fig. 1. B) Increasing concentrations of NaCl (150–950 mM) were added together with 250 kcpm 125I-FI to bacteria.
Averages of three independent experiments performed in duplicates are shown with error bars indicating SD and FI acquisition expressed as protein
bound relative to protein bound without addition of competitor. One-way ANOVA followed by Tukey’s post-hoc test was used for statistical analysis
(*** p,0.001).
doi:10.1371/journal.pone.0034852.g002
Figure 3. Degradation of 125I-C4b by FI bound to P. intermedia. A) P. intermedia ATCC 25611 was incubated at 56uC for 30 min and
subsequently 5 mg, 10 mg, and 15 mg FI (final concentration 125 ng/ml (1.42 mM), 250 ng/ml (2.84 mM) and 375 ng/ml (4.26 mM)) were added to the
bacterial suspension and samples incubated for 1 h at RT. Thereafter, bacteria were washed and mixed with E-64, C4met, C4BP and 125I-C4b. Samples
were incubated for 4 h at 37uC, centrifuged to remove bacteria followed by separation of proteins on a 10–15% SDS-PAGE gradient gel under
reducing conditions. Gels were dried and 125I-C4b was detected using a phosphorimager. Controls were samples only containing purified proteins
without bacteria; either FI and C4BP (positive control) or only FI without cofactor (negative control) were added to degradation reactions. B) Data
were quantified using the Image Gauge Software. Averages of four independent experiments are shown, error bars denoting the SD. The ratio of
C4d/a-chain was calculated and data from samples containing FI bound to bacteria compared to the control containing bacteria without FI using
one-way ANOVA followed by Tukey’s post-hoc test applied to samples containing bacteria (*** p,0.001; ** p,0.01; n.s., not significant). C) Effect of
elevated temperature on FI binding by P. intermedia. P. intermedia ATCC 25611 was incubated at 56uC or RT for 30 min and a binding assay was
performed with 250 kcpm 125I-labeled FI to exclude false positive binding by bacteria treated at elevated temperature. Data were compared to values
measured for samples incubated at RT using one-way ANOVA followed by Tukey’s post-hoc test (** p,0.01).
doi:10.1371/journal.pone.0034852.g003
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with unlabeled FI (Fig. 2A). The interaction between FI and its
bacterial ligand was intermediately sensitive to increasing ionic
strength as the binding in the presence of 550 mM NaCl was
decreased only by 50% thus indicating that the binding is only
partially determined by ionic interactions (Fig. 2B). The presence
of oxygen during the binding reaction did not lead to false positive
binding, for example, due to new epitopes accessible upon oxygen
exposure as similar results were obtained when experiments were
performed in anaerobic conditions (data not shown).
FI bound to P. intermedia ATCC 25611 retains its serine
protease activity
The data above indicate that P. intermedia strains bind FI possibly
providing protection from activated complement on the level of
C3 convertase. The retention of protease activity of FI is an
obligatory prerequisite for such a protective role of FI. To test
whether FI bound to P. intermedia retains its serine protease activity,
bacteria were first incubated at 56uC for 30 min in order to
minimize background degradation by bacterial proteases and then
incubated with purified FI. This procedure was adopted from the
routinely applied procedure to prepare serum for immunological
and protein binding experiments. Thereafter, FI activity was tested
with 125I-labeled C4b and C4BP as a cofactor. Cleavage of C4b
after incubation of the bacteria with increasing amounts of FI
resulted in an augmentation of the signal intensity of the C4d band
(Fig. 3A and B). The presence of bacteria alone caused some
background degradation resulting predominantly in a product
migrating faster than C4d. In order to exclude false positive
binding of FI due to the exposition of bacteria to elevated
temperature, binding of 125I-FI to P. intermedia ATCC 25611 was
tested after 30 min incubation of bacteria at RT or 56uC. We
observed that heat treatment caused a decrease in FI binding,
which might be due to partial denaturation of the bacterial ligand
(Fig. 3C). Thus this treatment does not cause an artifactual
increase in FI binding. Overall, these results indicate that FI
bound to P. intermedia ATCC 25611 retains its protease activity
resulting in specific degradation of C4b.
P. intermedia strains bind FI cofactors C4BP and FH
Since P. intermedia strains bind FI we tested whether these strains
also bind FI cofactors C4BP and FH. All P. intermedia strains
significantly bound C4BP (Fig. 4A) that was comparable to M.
catarrhalis RH4 and P. ginigivalis W83 and W50 (C4BP binding
positive controls). M. catarrhalis has been shown previously to
acquire C4BP on its surface via the ubiquitous surface proteins
UspA1 and UspA2 [24] and we found that the uspA1/uspA2
deletion mutant of RH4 (C4BP binding negative control) did not
bind C4BP that was consistent with published data. Likewise, E.
coli DH5a (C4BP binding negative control) did not acquire
significant amounts of C4BP. In parallel to the C4BP-binding, all
our P. intermedia strains also bound FH (Fig. 4B). S. pyogenes CCUG
25571 (FH binding positive control) has previously been shown to
bind FH [30], however binding appeared to be less efficient than
acquisition of FH by P. intermedia strains in this experimental set-
up, whereas S. aureus ATCC 25923 as well as E. coli DH5a (FH
binding negative controls) did not bind FH.
The binding of 125I-C4BP bound to P. intermedia ATCC 25611
could be reduced significantly by adding unlabelled C4BP (Fig. 5A)
and increasing ionic strength affected the interaction between 125I-
C4BP and bacteria only negligibly (Fig. 5B) implying hydrophobic
interaction. Further competition experiments with FH revealed
that 125I-FH could also be competed by adding unlabelled FH
(Fig. 5C). The interaction of P. intermedia ATCC 25611 with FH
was abrogated with increasing concentrations of NaCl (Fig. 5D)
suggesting an ionic binding mode for FH.
Binding of C4BP and FH by P. intermedia ATCC 25611
leads to increased degradation of C4b and C3b,
respectively
To test whether the binding of FI cofactors led to increased
complement inactivation by degradation of C4b and C3b we
preincubated heat-treated P. intermedia ATCC 25611 with
increasing amounts of C4BP and upon further incubation in the
presence of FI we found augmented generation of C4d (Fig. 6A).
Quantification of the signals confirmed a statistically significant
Figure 4. P. intermedia isolates bind purified FI cofactors C4BP and FH. The indicated P. intermedia strains, as well as A) M. catarrhalis RH 4, P.
gingivalis W50 and W83 (C4BP binding positive controls), M. catarrhalis DuspA1/2, and E. coli DH5a (C4BP binding negative controls) or B) S. pyogenes
CCUG 25571 (FH binding positive control), S. aureus ATCC 25923, and E. coli DH5a (FH binding negative controls) were mixed with (A) 500 kcpm 125I-
C4BP or (B) 125I-FH and incubated for 1 h at RT. Proteins bound to bacteria were detected as described in Fig. 1. Samples containing 125I-labeled
proteins that were incubated with buffer alone served as negative controls. Bars represent averages of three independent experiments performed in
duplicates and SD are indicated as error bars. One-way ANOVA and Tukey’s post-hoc test was used for statistical analysis as compared to negative
controls (*** p,0.001; * p,0.05; n.s., not significant).
doi:10.1371/journal.pone.0034852.g004
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increase in degradation of C4b in the presence of bound C4BP
(Fig. 6B). Bacterial cells incubated at elevated temperature bound
125I-C4BP equally well as those remaining at RT (Fig. 6C).
FH bound to P. intermedia ATCC 25611 also retained its
function as a cofactor for FI mediated cleavage of C3b. Thus we
found concentration dependent increase in band intensity of the
64 kDa and 43 kDa degradation products of C3b (Fig. 6D)
quantified by densitometry (Fig. 6E). Heat treatment of P.
intermedia ATCC 25611 resulted in a decrease of 125I-FH binding
to bacteria (Fig. 6F).
Taken together, the results presented here show that cofactors
C4BP and FH required for proteolytic activity of FI retain their
cofactor activity when bound to P. intermedia ATCC 25611.
Discussion
The ability to acquire complement inhibitors is an important
virulence mechanism and provides various bacterial pathogens with
a major advantage. To date, with a sole exception, only the binding
of the cofactors of FI by bacterial pathogens has been reported. FI
acquisition has exclusively been associated with the Gram-positive
S. aureus so far. Initially, it had been shown that C3b inactivation on
the surface of S. aureus is mediated by FI and FH and in this first
study binding of these proteins has been described [38]. Cleavage of
C3b was independent of the presence of cofactors [38] and led to
decreased phagocytosis efficiency by human polymorphonuclear
cells [22]. Clumping factor A could be identified as the ligand for FI
binding and a shed fragment of clumping factor A served as a
cofactor for FI-mediated cleavage of C3b [20,21].
Figure 5. Specificity and sensitivity of C4BP and FH binding by P. intermedia ATCC 25611. A) Binding of 250 kcpm 125I-C4BP was
competed by using 30 mg (final concentration 1.32 mM) unlabeled C4BP, C) 125I-FH binding by P. intermedia ATCC 25611 was competed by 7.5 mg
(final concentration 1.25 mM) unlabeled FH. The decrease of 125I-C4BP and 125I-FH binding was evaluated comparing the results of samples with and
without radiolabeled protein and bacteria. Samples without bacteria served as negative controls. The sensitivity of the interaction to ionic strength
was tested adding increasing concentrations of NaCl to binding reactions with B) 125I-C4BP and D) 125I-FH. Three independent experiments were
performed in duplicates; averages and SD were calculated and binding expressed as protein bound relative to protein bound without addition of
competitor. One-way ANOVA followed by Tukey’s post-hoc test was applied for statistical evaluation of the data (** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0034852.g005
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Our results suggest that FI in addition to cofactor acquisition
might be an important virulence mechanism of P. intermedia, the
infection of which is proposed to be of local, disseminated, acute,
as well as chronic nature [2–6] implying versatile solutions of this
pathogen to cope with the host response in the environment of
various niches, including gingival crevicular fluid in gingival or
periodontal pockets or in the lungs of patients afflicted with
aspiration pneumonia [42]. Previously, it was shown that the
periodontal pathogens P. intermedia and also P. gingivalis produce
proteases, which degrade complement proteins. Interpain A of P.
intermedia degrades the a-chain of purified C3 and this proteolytic
inactivation of C3 reduces the bactericidal activity of NHS and
makes interpain A expressing strains more resistant to killing by
complement [37]. A similar effect on NHS was also observed for P.
gingivalis strains W50 and W83. The proteases HRgpA, RgpB and
Kgp (gingipains) interfere with complement activation with
HRgpA and RgpB being most effective [43]. The mechanism
underlying this observation is predominantly the degradation of
C3, C4 and C5 a-chains [43,44]. Interestingly, interpain A and
gingipains exhibit a synergistic inhibitory activity on complement
activation [37]. This is in consistency with a model proposed for
periodontal biofilms in which both pathogens cooperate to prepare
a milieu favoring biofilm formation with help of their secreted
proteases. The bacterial proteases of P. intermedia and P. gingivalis
cause biphasic effects on complement activation, at low concen-
trations leading to activation of complement by C1 deposition and
generation of anaphylatoxins C3a and C5a. Low degree of
inflammation may be beneficial for the pathogens at this stage of
infection. Upon establishment of P. intermedia and P. gingivalis at the
site of infection, higher concentrations of proteases lead to
complement inhibition by degradation of C3, C4 and C5
[45,46]. Binding of FI, C4BP and FH might be a crucial
mechanism of complement evasion at low protease levels.
Accumulation of complement inhibitors of the host on bacteria
might even represent the backbone of P. intermedia immune
evasion, presumably being a rather passive interaction with
structural components of the bacterial envelope than being
dependent on secretion of active proteases. Furthermore, dissem-
inating bacteria are not protected by the environment of the
biofilm in the periodontal pocket. Thus, acquisition of comple-
ment inhibitors in the blood stream might provide the bacteria
with the ability to expand disease to a systemic level.
The production of the aforementioned proteases by periodontal
pathogens including P. intermedia made it necessary to distinguish
between inherent proteolytic activity of the bacteria themselves
and degradation mediated by FI and cofactors acquired by
bacteria. To this end it was necessary to adjust assay conditions by
using protease inhibitors and gentle heat treatment, which was
identical to that routinely used for inactivation of serum.
Incubation of the bacteria at 56uC caused a decrease in protein
binding, which was negligible in case of C4BP but still significant
for all the proteins examined in this study and could be due to
partial denaturing of the bacterial ligands potentially occurring
during incubation at this temperature. However, we sought to
prove that no artifactual binding of proteins upon heat treatment
led to false positive results testing the biological activity of protein
occupied by its ligand and we found no increase in protein
acquisition. Therefore, we conclude that FI, C4BP or FH bound
to P. intermedia ATCC 25611 after incubation at 56uC for 30 min
retain their activity in degrading C3b or C4b. The binding studies
with these proteins show a specific and strong binding to all P.
intermedia strains tested and reduced binding capacity of bacteria
after heat treatment does not affect the activity of the proteins
bound by bacteria. It appears worth noting that we observed high
binding for the three complement inhibitors presented here in this
study. However, it is not a general phenomenon of P. intermedia
strains to bind a broad variety of complement proteins in an
unspecific manner. Besides FI, C4BP, and FH we also tested
binding of the membrane cofactor protein CD46 in a similar
experimental set-up and observed very low binding (below 5%) for
the P. intermedia strains tested (data not shown).
Taken together, besides complement evasion mediated by
proteases produced by P. intermedia, complement inhibitor
acquisition might be beneficial at low concentrations of the
inherent proteases, and various mechanisms have to be regarded
as pieces of the puzzle drawing the complete picture of immune
evasion, preparation of an ideal microenvironment, and poten-
tially dissemination of P. intermedia.
Moreover, binding of FH to bacterial cells promotes adherence
and invasion of epithelial cells as has been shown for Streptococcus
pneumoniae. Glycosaminoglycans on host cells serve as a receptor for
FH mediated adherence of S. pneumoniae subsequently followed by
integrin dependent internalization of the bacilli [47]. Similar to
FH, C4BP interacts with ligands on host cells thereby also possibly
promoting bacteria host cell interaction. Heparin and chondroitin
sulfate are glycosaminoglycan ligands known to be involved in
C4BP and FH host cell interaction [48–50]. If adherence to host
cells is mediated by C4BP and FH bound by P. intermedia will be
subject of future studies.
Here we provide data indicating that FI, C4BP and FH
acquisition might be an additional mechanism of complement
evasion. Binding of these complement inhibitors draws the
attention towards host proteins, in particular complement, bound
by P. intermedia and its significance during the course of infection.
Detailed investigation of the role of complement inhibitor
acquisition in interaction with host cells and definition of the
bacterial ligands of this interplay will be addressed in the future in
order to contribute to the understanding of the role of P. intermedia
in outcome of disease.
Figure 6. C4BP and FH bound to P. intermedia ATCC 25611 retain their cofactor activity. P. intermedia ATCC 25611 was incubated for
30 min at 56uC and subsequently incubated with C4BP (5–15 mg) (final concentration 125 ng/ml (0.22 mM), 250 ng/ml (0.44 mM) and 375 ng/ml
(0.66 mM)) (A) and B)) or FH (1–5 mg) (final concentration 0.025 mg/ml (0.16 mM), 0.05 mg/ml (0.32 mM), 0.125 mg/ml (0.8 mM)) (D) and E)) for 1 h at RT.
Samples without C4BP and FH were used as a reference. Bacteria were washed and transferred to fresh reaction tubes. A) and B) Bacteria were mixed
with E-64, C4met, FI and trace amounts of 125I-C4b. Samples were incubated for 1.5 h at 37uC, centrifuged and proteins separated on a 10–15% SDS-
PAGE gradient gel under reducing conditions. Samples without bacteria, which contained C4BP but no FI served as negative controls. Samples
supplemented with C4BP and FI were positive controls in this experimental setup. B) and E) Protein bands were quantified using the Image Gauge
Software. C) and F) P. intermedia ATCC 25611 was incubated at 56uC for 30 min and binding assays were performed as described earlier with 125I-
labeled protein. D) and E) Bacterial suspensions were mixed with E-64, C3met, FI and trace amounts of 125I-C3b. Samples were incubated for 1.5 h at
37uC and separated as described above. A negative control without bacteria was included, in which FI was omitted. A positive control without
bacteria supplemented with FH and FI was prepared. All experiments were performed in triplicates, the mean values and SD were calculated. One-
way ANOVA and Tukey’s post-hoc test were used for statistical analysis on bacteria containing samples. Degradation mediated by cofactors bound to
P. intermedia was evaluated by comparing the ratios of C4d or a943 degradation products to a-chains of samples where protein was omitted during
preincubation (*** p#0.001; ** p,0.01; * p,0.05; n.s., not significant).
doi:10.1371/journal.pone.0034852.g006
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